J-Matthias Graf von der Schulenburg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4189015/publications.pdf

Version: 2024-02-01

20 papers 859 citations

687363 13 h-index 610901 24 g-index

27 all docs

27 docs citations

times ranked

27

1406 citing authors

#	Article	IF	Citations
1	German Value Set for the EQ-5D-5L. Pharmacoeconomics, 2018, 36, 663-674.	3.3	316
2	German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus. Value in Health, 2008, 11, 539-544.	0.3	138
3	Applying the Analytic Hierarchy Process in healthcare research: A systematic literature review and evaluation of reporting. BMC Medical Informatics and Decision Making, 2015, 15, 112.	3.0	124
4	<i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1254-1261.	2.5	38
5	Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems. European Journal of Health Economics, 2015, 16, 113-118.	2.8	36
6	Cost analysis of whole genome sequencing in German clinical practice. European Journal of Health Economics, 2017, 18, 623-633.	2.8	27
7	Comparison of different approaches applied in Analytic Hierarchy Process – an example of information needs of patients with rare diseases. BMC Medical Informatics and Decision Making, 2016, 16, 117.	3.0	25
8	Costs and treatment patterns of incident ADHD patients - a comparative analysis before and after the initial diagnosis Health Economics Review, 2015, 5, 40.	2.0	19
9	Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. European Journal of Health Economics, 2017, 18, 273-292.	2.8	18
10	Therapy preferences of patients with lung and colon cancer: a discrete choice experiment. Patient Preference and Adherence, 2017, Volume 11, 1647-1656.	1.8	18
11	Evaluation of two family-based intervention programs for children affected by rare disease and their families – research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design. BMC Family Practice, 2020, 21, 239.	2.9	18
12	Benefit assessment in Germany: implications for price discounts. Health Economics Review, 2016, 6, 33.	2.0	16
13	Valuation of the EQ-5D-5L with composite time trade-off for the German population – an exploratory study. Health and Quality of Life Outcomes, 2017, 15, 39.	2.4	16
14	Use and importance of different information sources among patients with rare diseases and their relatives over time: a qualitative study. BMC Public Health, 2020, 20, 860.	2.9	13
15	Telephone health services in the field of rare diseases: a qualitative interview study examining the needs of patients, relatives, and health care professionals in Germany. BMC Health Services Research, 2018, 18, 99.	2.2	12
16	Patient-reported data informing early benefit assessment of rare diseases in Germany: A systematic review. Health Economics Review, 2019, 9, 34.	2.0	6
17	Costs of isocyanate-related occupational diseases: A systematic review. Journal of Occupational and Environmental Hygiene, 2019, 16, 446-466.	1.0	4
18	The Role of decision-analytic modelling in German health technology assessments. Health Economics Review, $2015, 5, 7$.	2.0	1

#	Article	IF	CITATIONS
19	Authors' reply to Gandjour: "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany― European Journal of Health Economics, 2018, 19, 473-481.	2.8	1
20	Conceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study. JMIR Research Protocols, 2018, 7, e112.	1.0	1